{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:28:01Z","timestamp":1793672881009,"version":"4.5.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09347-z","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:43:23Z","timestamp":1788759803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of cannabinoid-based interventions for behavioral and cognitive symptoms in dementia: systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Gabriel Caruso Novaes","family":"Tudella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7526-7946","authenticated-orcid":false,"given":"Augusto Utida","family":"Klostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana","family":"Menegucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Vitor Andrade","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro Gon\u00e7alves","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"9347_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/JMDH.S17773","volume":"4","author":"JH Grand","year":"2011","unstructured":"Grand JH, Caspar S, Macdonald SW (2011) Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc 4:125\u2013147. https:\/\/doi.org\/10.2147\/JMDH.S17773","journal-title":"J Multidiscip Healthc"},{"issue":"Suppl 1","key":"9347_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt198","volume":"5","author":"H Chertkow","year":"2013","unstructured":"Chertkow H, Feldman HH, Jacova C, Massoud F (2013) Definitions of dementia and predementia states in Alzheimer\u2019s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther 5(Suppl 1):S2. https:\/\/doi.org\/10.1186\/alzrt198","journal-title":"Alzheimers Res Ther"},{"issue":"10452","key":"9347_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY et al (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404(10452):572\u2013628. https:\/\/doi.org\/10.1016\/S0140-6736(24)01296-0","journal-title":"Lancet"},{"issue":"13","key":"9347_CR4","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1056\/NEJMc1509349","volume":"373","author":"SL Mitchell","year":"2015","unstructured":"Mitchell SL (2015) Advanced Dementia. N Engl J Med 373(13):1276\u20131277. https:\/\/doi.org\/10.1056\/NEJMc1509349","journal-title":"N Engl J Med"},{"issue":"2","key":"9347_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/gps.1858","volume":"23","author":"M Steinberg","year":"2008","unstructured":"Steinberg M, Shao H, Zandi P et al (2008) Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23(2):170\u2013177. https:\/\/doi.org\/10.1002\/gps.1858","journal-title":"Int J Geriatr Psychiatry"},{"issue":"39","key":"9347_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18390","volume":"18","author":"G Livingston","year":"2014","unstructured":"Livingston G, Kelly L, Lewis-Holmes E et al (2014) A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess 18(39):1\u2013vi. https:\/\/doi.org\/10.3310\/hta18390","journal-title":"Health Technol Assess"},{"issue":"15","key":"9347_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15):1934\u20131943. https:\/\/doi.org\/10.1001\/jama.294.15.1934","journal-title":"JAMA"},{"issue":"3","key":"9347_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14(3):191\u2013210. https:\/\/doi.org\/10.1097\/01.JGP.0000200589.01396.6d","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7489","key":"9347_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/bmj.38330.470486.8F","volume":"330","author":"SS Gill","year":"2005","unstructured":"Gill SS, Rochon PA, Herrmann N et al (2005) Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 330(7489):445. https:\/\/doi.org\/10.1136\/bmj.38330.470486.8F","journal-title":"BMJ"},{"issue":"3","key":"9347_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1017\/S1041610209991505","volume":"22","author":"S Gauthier","year":"2010","unstructured":"Gauthier S, Cummings J, Ballard C et al (2010) Management of behavioral problems in Alzheimer\u2019s disease. Int Psychogeriatr 22(3):346\u2013372. https:\/\/doi.org\/10.1017\/S1041610209991505","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"9347_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/1568026619666190128125912","volume":"19","author":"M Saxena","year":"2019","unstructured":"Saxena M, Dubey R (2019) Target enzyme in Alzheimer\u2019s disease: acetylcholinesterase inhibitors. Curr Top Med Chem 19(4):264\u2013275. https:\/\/doi.org\/10.2174\/1568026619666190128125912","journal-title":"Curr Top Med Chem"},{"key":"9347_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.bioorg.2019.03.064","volume":"87","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yang Y, Hong KH et al (2019) Design, synthesis and evaluation of a novel metal chelator as multifunctional agents for the treatment of Alzheimer\u2019s disease. Bioorg Chem 87:720\u2013727. https:\/\/doi.org\/10.1016\/j.bioorg.2019.03.064","journal-title":"Bioorg Chem"},{"issue":"1","key":"9347_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JAD-180595","volume":"67","author":"L Fr\u00f6lich","year":"2019","unstructured":"Fr\u00f6lich L, Atri A, Ballard C et al (2019) Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate Alzheimer\u2019s disease. J Alzheimers Dis 67(1):303\u2013313. https:\/\/doi.org\/10.3233\/JAD-180595","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"9347_CR14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2174\/156720512801322564","volume":"9","author":"D Olivares","year":"2012","unstructured":"Olivares D, Deshpande VK, Shi Y et al (2012) N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer\u2019s disease, vascular dementia and Parkinson\u2019s disease. Curr Alzheimer Res 9(6):746\u2013758. https:\/\/doi.org\/10.2174\/156720512801322564","journal-title":"Curr Alzheimer Res"},{"issue":"12","key":"9347_CR15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","volume":"288","author":"CG Lyketsos","year":"2002","unstructured":"Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288(12):1475\u20131483. https:\/\/doi.org\/10.1001\/jama.288.12.1475","journal-title":"JAMA"},{"issue":"7","key":"9347_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/gps.1722","volume":"22","author":"SU Zuidema","year":"2007","unstructured":"Zuidema SU, Derksen E, Verhey FR, Koopmans RT (2007) Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. Int J Geriatr Psychiatry 22(7):632\u2013638. https:\/\/doi.org\/10.1002\/gps.1722","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"9347_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1055\/a-2262-7837","volume":"57","author":"B Broers","year":"2024","unstructured":"Broers B, Bianchi F (2024) Cannabinoids for behavioral symptoms in dementia: an overview. Pharmacopsychiatry 57(3):160\u2013168. https:\/\/doi.org\/10.1055\/a-2262-7837","journal-title":"Pharmacopsychiatry"},{"issue":"17","key":"9347_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179472","volume":"22","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Bryant J, Ngwa W (2021) The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci 22(17):9472. https:\/\/doi.org\/10.3390\/ijms22179472","journal-title":"Int J Mol Sci"},{"issue":"4","key":"9347_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3233\/JAD-141635","volume":"43","author":"G Bedse","year":"2015","unstructured":"Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S (2015) The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease. J Alzheimers Dis 43(4):1115\u20131136. https:\/\/doi.org\/10.3233\/JAD-141635","journal-title":"J Alzheimers Dis"},{"key":"9347_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.762738","volume":"12","author":"I Gallego-Landin","year":"2021","unstructured":"Gallego-Landin I, Garc\u00eda-Baos A, Castro-Zavala A, Valverde O (2021) Reviewing the role of the endocannabinoid system in the pathophysiology of depression. Front Pharmacol 12:762738. https:\/\/doi.org\/10.3389\/fphar.2021.762738","journal-title":"Front Pharmacol"},{"issue":"2","key":"9347_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1545109707300157","volume":"6","author":"E DeJesus","year":"2007","unstructured":"DeJesus E, Rodwick BM, Bowers D, Cohen CJ, Pearce D (2007) Use of dronabinol improves appetite and reverses weight loss in HIV\/AIDS-infected patients. J Int Assoc Physicians AIDS Care (Chic) 6(2):95\u2013100. https:\/\/doi.org\/10.1177\/1545109707300157","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"4","key":"9347_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.fbp.0000135704.56422.40","volume":"15","author":"J Haller","year":"2004","unstructured":"Haller J, Varga B, Ledent C, Freund TF (2004) CB1 cannabinoid receptors mediate anxiolytic effects. Behav Pharmacol 15(4):299\u2013304. https:\/\/doi.org\/10.1097\/01.fbp.0000135704.56422.40","journal-title":"Behav Pharmacol"},{"issue":"1\u20132","key":"9347_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0304-3959(03)00163-5","volume":"105","author":"M Naef","year":"2003","unstructured":"Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC\u2013morphine combination in healthy subjects. Pain 105(1\u20132):79\u201388. https:\/\/doi.org\/10.1016\/S0304-3959(03)00163-5","journal-title":"Pain"},{"issue":"5","key":"9347_CR24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.2174\/187152710793361568","volume":"9","author":"T Bisogno","year":"2010","unstructured":"Bisogno T, Di Marzo V (2010) Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 9(5):564\u2013573. https:\/\/doi.org\/10.2174\/187152710793361568","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"4","key":"9347_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1517\/14728222.2012.671812","volume":"16","author":"T Karl","year":"2012","unstructured":"Karl T, Cheng D, Garner B, Arnold JC (2012) The therapeutic potential of the endocannabinoid system for Alzheimer\u2019s disease. Expert Opin Ther Targets 16(4):407\u2013420. https:\/\/doi.org\/10.1517\/14728222.2012.671812","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"9347_CR26","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","volume":"27","author":"N Herrmann","year":"2019","unstructured":"Herrmann N, Ruthirakuhan M, Gallagher D et al (2019) Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease. Am J Geriatr Psychiatry 27(11):1161\u20131173. https:\/\/doi.org\/10.1016\/j.jagp.2019.05.002","journal-title":"Am J Geriatr Psychiatry"},{"key":"9347_CR27","doi-asserted-by":"publisher","unstructured":"Albertyn CP, Guu TW, Chu P et al (2025) Sativex (nabiximols) for the treatment of agitation and aggression in Alzheimer\u2019s dementia. Age Ageing 54(6):afaf149. https:\/\/doi.org\/10.1093\/ageing\/afaf149","DOI":"10.1093\/ageing\/afaf149"},{"key":"9347_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251389608","author":"RM Cury","year":"2025","unstructured":"Cury RM, da Silva T, Cezar-Dos-Santos F et al (2025) A randomized clinical trial of low-dose cannabis extract in Alzheimer\u2019s disease. J Alzheimers Dis. https:\/\/doi.org\/10.1177\/13872877251389608","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"9347_CR29","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1097\/MJT.0000000000001120","volume":"27","author":"H Paunescu","year":"2020","unstructured":"Paunescu H, Dima L, Ghita I et al (2020) A systematic review of clinical studies on psychoactive cannabinoids in Alzheimer dementia. Am J Ther 27(3):e249\u2013e269. https:\/\/doi.org\/10.1097\/MJT.0000000000001120","journal-title":"Am J Ther"},{"issue":"9","key":"9347_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012820.pub2","volume":"9","author":"D Bosnjak Kuharic","year":"2021","unstructured":"Bosnjak Kuharic D, Markovic D, Brkovic T et al (2021) Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 9(9):CD012820. https:\/\/doi.org\/10.1002\/14651858.CD012820.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"9347_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"9347_CR32","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews. Cochrane Database Syst Rev 10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","DOI":"10.1002\/14651858.ED000142"},{"key":"9347_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"7650","key":"9347_CR34","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"3","key":"9347_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00391-007-0420-z","volume":"40","author":"R Mahlberg","year":"2007","unstructured":"Mahlberg R, Walther S (2007) Actigraphy in agitated patients with dementia. Z Gerontol Geriatr 40(3):178\u2013184. https:\/\/doi.org\/10.1007\/s00391-007-0420-z","journal-title":"Z Gerontol Geriatr"},{"key":"9347_CR36","doi-asserted-by":"publisher","unstructured":"Rosenberg PB, Amjad H, Burhanullah H et al (2025) Dronabinol for agitation in Alzheimer\u2019s disease: RCT. Am J Geriatr Psychiatry. Published online November 10, 2025. https:\/\/doi.org\/10.1016\/j.jagp.2025.10.004","DOI":"10.1016\/j.jagp.2025.10.004"},{"issue":"9","key":"9347_CR37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS572>3.0.CO;2-I","volume":"12","author":"L Volicer","year":"1997","unstructured":"Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997) Effects of dronabinol on anorexia and disturbed behavior in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 12(9):913\u2013919. https:\/\/doi.org\/10.1002\/(SICI)1099-1166(199709)12:9%3c913::AID-GPS572%3e3.0.CO;2-I","journal-title":"Int J Geriatr Psychiatry"},{"key":"9347_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.951889","volume":"9","author":"V Hermush","year":"2022","unstructured":"Hermush V, Ore L, Stern N et al (2022) Effects of rich cannabidiol oil on behavioral disturbances in dementia. Front Med (Lausanne) 9:951889. https:\/\/doi.org\/10.3389\/fmed.2022.951889","journal-title":"Front Med (Lausanne)"},{"issue":"23","key":"9347_CR39","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","volume":"84","author":"GA van den Elsen","year":"2015","unstructured":"van den Elsen GA, Ahmed AI, Verkes RJ et al (2015) Tetrahydrocannabinol for neuropsychiatric symptoms in dementia. Neurology 84(23):2338\u20132346. https:\/\/doi.org\/10.1212\/WNL.0000000000001675","journal-title":"Neurology"},{"issue":"2","key":"9347_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0269881116665357","volume":"31","author":"GA van den Elsen","year":"2017","unstructured":"van den Elsen GA, Tobben L, Ahmed AI et al (2017) Effects of tetrahydrocannabinol on balance and gait in dementia. J Psychopharmacol 31(2):184\u2013191. https:\/\/doi.org\/10.1177\/0269881116665357","journal-title":"J Psychopharmacol"},{"issue":"3","key":"9347_CR41","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1124\/jpet.107.121566","volume":"322","author":"G Esposito","year":"2007","unstructured":"Esposito G, Iuvone T, Savani C et al (2007) Opposing control of cannabinoid receptor stimulation on amyloid-\u03b2\u2013induced reactive gliosis. J Pharmacol Exp Ther 322(3):1144\u20131152. https:\/\/doi.org\/10.1124\/jpet.107.121566","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"9347_CR42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","volume":"34","author":"M Solas","year":"2013","unstructured":"Solas M, Francis PT, Franco R, Ramirez MJ (2013) CB2 receptor and amyloid pathology in Alzheimer\u2019s disease. Neurobiol Aging 34(3):805\u2013808. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.06.005","journal-title":"Neurobiol Aging"},{"issue":"6","key":"9347_CR43","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nm.4311","volume":"23","author":"A Bilkei-Gorzo","year":"2017","unstructured":"Bilkei-Gorzo A, Albayram O, Draffehn A et al (2017) A chronic low dose of THC restores cognitive function in old mice. Nat Med 23(6):782\u2013787. https:\/\/doi.org\/10.1038\/nm.4311","journal-title":"Nat Med"},{"issue":"2\u20133 Suppl","key":"9347_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","volume":"28","author":"T Karl","year":"2017","unstructured":"Karl T, Garner B, Cheng D (2017) The therapeutic potential of cannabidiol for Alzheimer\u2019s disease. Behav Pharmacol 28(2\u20133 Suppl):142\u2013160. https:\/\/doi.org\/10.1097\/FBP.0000000000000247","journal-title":"Behav Pharmacol"},{"key":"9347_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19433","author":"M Hsu","year":"2025","unstructured":"Hsu M, Shah A, Jordan A, Gold MS, Hill KP (2025) Therapeutic use of cannabis and cannabinoids: a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.19433. (Published online November 26,)","journal-title":"JAMA"},{"issue":"1","key":"9347_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/07317115.2020.1742832","volume":"44","author":"T Charernboon","year":"2021","unstructured":"Charernboon T, Lerthattasilp T, Supasitthumrong T (2021) Effectiveness of cannabinoids for treatment of dementia: a systematic review of randomized controlled trials. Clin Gerontol 44(1):16\u201324. https:\/\/doi.org\/10.1080\/07317115.2020.1742832","journal-title":"Clin Gerontol"},{"issue":"7","key":"9347_CR47","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG et al (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311(7):682\u2013691. https:\/\/doi.org\/10.1001\/jama.2014.93","journal-title":"JAMA"},{"issue":"10310","key":"9347_CR48","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0140-6736(21)01210-1","volume":"398","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, High J, Stirling S et al (2021) Study of mirtazapine for agitated behaviours in dementia (SYMBAD): RCT. Lancet 398(10310):1487\u20131497. https:\/\/doi.org\/10.1016\/S0140-6736(21)01210-1","journal-title":"Lancet"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09347-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09347-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09347-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:03:05Z","timestamp":1793671385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09347-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9347"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09347-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest, no funding, and no prior presentation of this study. All figures are original and created by the authors.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"762"}}